Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
Ocular Therapeutix randomizes first patient in HELIOS-3 | Ophthalmology Times
(Image Credit: AdobeStock/ronstik) Ocular Therapeutix has randomized the first patient in its HELIOS-3 phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR). The company describes AXPAXLI as an investigational, bioresorbable, intravitreal hydrogel incorporating…
AAO 2025 Takeaways: How imaging and remote monitoring are transforming retinal care | Ophthalmology Times
(Image Credit: AdobeStock/Mohwet) Editor’s Note: This content was generated with the assistance of AI. AAO 2025 showcased some of the most significant leaps in retinal imaging and disease surveillance the field has seen in over a decade. Three presentations—delivered by…
Orasis Pharmaceuticals introduces starter packs of pilocarpine hydrochloride ophthalmic solution 0.4% | Ophthalmology Times
(Image Credit: AdobeStock/bankoo) Orasis Pharmaceuticals announced the availability of Starter Packs of Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% to “broaden access for patients seeking a flexible option to manage their presbyopia and allow greater first-hand experience for eye care professionals.”1…
Regeneron’s EYLEA HD injection 8 mg approved by FDA for the treatment of macular edema following RVO | Ophthalmology Times
The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals for the treatment of patients with macular edema following retinal vein occlusion (RVO) with up to every 8-week dosing after an initial monthly…
EyePoint receives second consecutive positive recommendation from DSMC | Ophthalmology Times
(Image credit: ©peopleimages.com/AdobeStock) The Data Safety Monitoring Committee (DSMC) recently completed its second scheduled review of EyePoint Pharmaceuticals’ ongoing phase 3 trial evaluating DURAVYU for the treatment of wet AMD (wAMD), EyePoint announced.1 The DSMC concluded that both the LUGANO…
Limitations of Current Dry Eye Therapies | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Treatment Selection in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Harrow completes acquisiton of Melt Pharmaceuticals | Ophthalmology Times
(Image Credit: AdobeStock/Parradee) Harrow has completed the acquisition of Melt Pharmaceuticals, which includes product candidates MELT-210, MELT-300, and MELT-400 based on the Zydis ODT (oral dissolving tablet) drug delivery platform. Melt will now be fully integrated into Harrow’s operations to…
Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1 | Ophthalmology Times
(Image Credit: AdobeStock/Treecha) Opus Genetics has dosed the first patient in its OPGx-BEST1 phase 1/2 clinical trial, BIRD-1, for Best disease (BEST1). Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by…
FDA accepts resubmitted ONS-5010 BLA from Outlook Therapeutics | Ophthalmology Times
(Image Credit: AdobeStock) The FDA has accepted for review a biologics license application (BLA) from Outlook Therapeutics for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). ONS-5010 is a recombinant humanized monoclonal antibody (mAb) that selectively…